Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Visual field defects in patients taking vigabatrin.

A Midelfart1, E Midelfart, E Brodtkorb

  • 1Department of Ophthalmology, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim. anna.midelfart@medisin.ntnu.no

Acta Ophthalmologica Scandinavica
|October 19, 2000
PubMed
Summary

Long-term vigabatrin use, an antiepileptic drug, is linked to frequent visual field defects. This study found significant peripheral constriction and nasal visual field loss in patients undergoing vigabatrin therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alcohol withdrawal syndrome: mechanisms, manifestations, and management.

Acta neurologica Scandinavica·2016
Same author

ADCK3 mutations with epilepsy, stroke-like episodes and ataxia: a POLG mimic?

European journal of neurology·2016
Same author

Vision problems in ischaemic stroke patients: effects on life quality and disability.

European journal of neurology·2015
Same author

Common imitators of epilepsy.

Acta neurologica Scandinavica. Supplementum·2012
Same author

Visual impairment in stroke patients--a review.

Acta neurologica Scandinavica. Supplementum·2012
Same author

Comparison of carbamazepine rash in multiple sclerosis and epilepsy.

Acta neurologica Scandinavica·2011

Area of Science:

  • Ophthalmology
  • Neurology
  • Pharmacology

Background:

  • Vigabatrin is an antiepileptic drug used for treating epilepsy.
  • Recent reports suggest vigabatrin may cause visual disturbances.
  • Long-term effects of vigabatrin on vision require thorough investigation.

Purpose of the Study:

  • To investigate the prevalence and characteristics of visual field loss in patients on long-term vigabatrin treatment.
  • To assess the impact of vigabatrin on visual function in epilepsy patients.

Main Methods:

  • Automated perimetry (Humphrey Field Analyser) was used to examine visual fields up to 60 degrees from fixation in 18 patients on vigabatrin.
  • Five epilepsy patients on other medications served as controls.
  • Ophthalmologic examinations were conducted for patients with identified visual field defects.

Related Experiment Videos

Main Results:

  • Visual field defects were observed in a significant proportion of patients on vigabatrin.
  • Mild defects were noted in 33% of right eyes and 44.4% of left eyes; severe defects in 50% of right eyes and 44.4% of left eyes.
  • The most common defect pattern was peripheral constriction with nasal predominance, confirmed by additional perimetry.

Conclusions:

  • Visual field defects associated with vigabatrin therapy may be more common than previously recognized.
  • The findings highlight the importance of regular ophthalmologic monitoring for patients on long-term vigabatrin treatment.
  • Further research is warranted to understand the mechanisms and long-term prognosis of vigabatrin-induced visual field loss.